1. Norway Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
PCI Biotech Holding ASA

PCI Biotech Holding ASA

PCIB.OL
PCI Biotech Holding ASANO flagOslo Stock Exchange
0.07
NOK
- -
- -
2.61MMarket Cap
PCI Biotech Holding ASA
PCIB.OL
(Oslo Stock Exchange)

Recent

price

0.07

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
0.95
0.94
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-1.65
-1.26
-1.07
-1.97
-2.14
-3.22
-2.12
-2.01
-1.76
-1.25
-3.19
-1.94
-2.37
-1.48
-0.54
-0.44
-0.78
Basic EPS, GAAP
-1.87
-0.96
-1.48
-1.9
-2.22
-2.85
-2.18
-2.22
-1.26
-1.45
-2.94
-2.08
-1.83
-1.58
-0.4
-0.37
-0.81
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-6.05
-5.61
-5.91
-7.87
-2.58
-6.08
-5.08
-6.7
-4.74
-3.94
-7.03
-7.01
-9.02
1.54
0.03
0.03
3
Book Value per Share
3.86
9.52
7.2
5.43
3.36
0.82
2.94
0.82
1.72
12.23
9.17
5.08
3.05
1.54
1.04
0.63
1.26
Tangible Book Value per Share
9
11
13
13
13
11
15
16
24
28
28
37
37
37
38
37
37
Basic Weighted Avg Shares
9
10
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-205.36
-155.52
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
2
3
6
- -
- -
1
Depreciation Expense
-15
-14
-14
-25
-28
-36
-32
-32
-43
-35
-89
-72
-88
-55
-20
-16
-29
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-174.35
-133.47
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
35
108
94
71
43
9
44
13
44
340
251
181
107
57
39
23
47
Working Capital
- -
3
2
- -
- -
- -
- -
- -
- -
- -
1
- -
1
- -
- -
- -
- -
LT Debt
35
105
93
70
43
9
44
13
42
340
255
189
114
57
39
23
47
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-69.43
-1,467.11
-8.63
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
37
37
Market Capitalization
77
77
79

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
63
57
52
Cash, Cash Equivalents & STI
56
51
46
Accounts Receivable, Net
- -
6
6
Inventories
- -
- -
- -
Total Current Liabilities
6
5
5
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
103.56%
-37.41%
-39.93%
Free Cash Flow
1.94%
-22.66%
-8.1%
Net Income, GAAP
4.31%
-23.25%
-19.19%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.16
-0.15
- -
- -
-0.54
2024
- -
- -
- -
- -
-0.44
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Hemostemix Inc (HMTXF)
Arcturus Therapeutics Holdings Inc. (ARCT)
JW (Cayman) Therapeutics Co. Ltd (JWCTF)
Cellectar Biosciences, Inc. (CLRB)
Atreca, Inc. (BCEL)
Stealth BioTherapeutics Corp (MITO)
Business
PCI Biotech Holding ASA PCI Biotech Holding ASA, a biopharmaceutical company listed on the Oslo Stock Exchange, develops and commercializes technologies and novel therapies based on its proprietary photochemical platform, including photochemical lysis (PCL) for enhancing viral vector manufacturing yield and purity in gene therapy bioprocessing, and photochemical internalization (PCI) for light-triggered intracellular release of therapeutics in areas such as immunotherapy, dermatology, and oncology. The platform utilizes the small molecule photosensitizer fimaporfin (Amphinex) combined with a light source to enable targeted drug delivery, supporting applications like fimaCHEM for enhancing chemotherapeutic drugs in localized cancer treatment, fimaVACC for inducing T-cell responses in therapeutic cancer vaccination, and fimaNAc for nucleic acid therapeutics in dermatological diseases; the company operates primarily in research and development with a focus on oncology and gene therapy markets in Europe. Founded in 2007 and headquartered in Oslo, Norway, at Oslo Cancer Cluster Innovation Park, PCI Biotech Holding ASA targets pharmaceutical and biotech partners globally through its partnering model. In August 2025, the company discontinued development of its PCL technology for viral vector bioprocessing and initiated an evaluation of future operations, as announced in its half-year 2025 interim report and subsequent updates in September and October 2025; recent activities include recruitment of key scientific personnel such as a new Chief Scientific Officer in early 2025 with associated employee share option schemes, alongside routine financial reporting and annual general meetings in 2025.